9 results  1 of 1 

1 Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
Byung Wan Lee, KyungWan Min, Eun-Gyoung Hong, Bon Jeong Ku, Jun Goo Kang, Suk Chon, Won-Young Lee, Mi Kyoung Park, Jae Hyeon Kim, Sang Yong Kim, Keeho Song, Soon Jib Yoo
Endocrinol Metab.2023;38(3):328-337.   Published online 2023 June 28     DOI: http://dx.doi.org/10.3803/EnM.2023.1688
      
2 The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-World Data Study
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek
Diabetes Metab J.2023;47(1):135-139.   Published online 2022 April 29     DOI: http://dx.doi.org/10.4093/dmj.2021.0373
      
3 Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
Chi-Ho Lee, Mei-Zhen Wu, David Tak-Wai Lui, Darren Shing-Hei Chan, Carol Ho-Yi Fong, Sammy Wing-Ming Shiu, Ying Wong, Alan Chun-Hong Lee, Joanne King-Yan Lam, Yu-Cho Woo, Karen Siu-Ling Lam, Kelvin Kai-Hang Yiu, Kathryn Choon-Beng Tan
Diabetes Metab J.2022;46(6):843-854.   Published online 2022 April 28     DOI: http://dx.doi.org/10.4093/dmj.2021.0319
      
4 Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
Diabetes Metab J.2021;45(3):339-348.   Published online 2020 May 28     DOI: http://dx.doi.org/10.4093/dmj.2019.0203
      
5 Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
Jun Hwa Hong
J Korean Diabetes.2019;20(2):87-91.   Published online 2019 June 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.2.87
      
6 Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
Sang Hyun Park, Young Ju Choi, Eun-Jung Rhee, Kab Bum Huh
Endocrinol Metab.2019;34(1):70-79.   Published online 2019 March 21     DOI: http://dx.doi.org/10.3803/EnM.2019.34.1.70
   
7 Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
Kyu Hang Lee, Sang Don Lee, Namdu Kim, Kwee Hyun Suh, Young Hoon Kim, Sang Soo Sim
Korean J Physiol Pharmacol.2019;23(1):55-62.   Published online 2018 December 26     DOI: http://dx.doi.org/10.4196/kjpp.2019.23.1.55
      
8 The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review
Hyung Woo Lee, Sun Joon Moon, Hee Sim Han, Eun Jeong Shin, Jin Hee Baek, Hyun-Joo Han, Young Min Cho, Kwi Suk Kim
J Korean Diabetes.2017;18(4):275-283.   Published online 2017 January 10     DOI: http://dx.doi.org/10.4093/jkd.2017.18.4.275
   
9 A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Chang Hee Jung, Jung Eun Jang, Joong-Yeol Park
Diabetes Metab J.2014;38(4):261-273.   Published online 2014 August 20     DOI: http://dx.doi.org/10.4093/dmj.2014.38.4.261
      

 1 of 1